K
Kevin A. Ault
Researcher at University of Kansas
Publications - 72
Citations - 7986
Kevin A. Ault is an academic researcher from University of Kansas. The author has contributed to research in topics: Cervical cancer & Vaccination. The author has an hindex of 27, co-authored 72 publications receiving 7472 citations. Previous affiliations of Kevin A. Ault include University of Iowa & United States Department of Health and Human Services.
Papers
More filters
Journal ArticleDOI
A controlled trial of a human papillomavirus type 16 vaccine.
Laura A. Koutsky,Kevin A. Ault,Cosette M. Wheeler,Darron R. Brown,Eliav Barr,Frances B. Alvarez,Lisa M. Chiacchierini,Kathrin U. Jansen +7 more
TL;DR: Administration of this HPV- 16 vaccine reduced the incidence of both HPV-16 infection and HPV-15-related cervical intraepithelial neoplasia, and immunizing HPV-14-negative women may eventually reduce the probability of cervical cancer.
Journal ArticleDOI
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
Luisa L. Villa,Ronaldo L.R. Costa,Carlos Alberto Petta,Rosires Pereira de Andrade,Kevin A. Ault,Anna R. Giuliano,Cosette M. Wheeler,Laura A. Koutsky,Christian Malm,Matti Lehtinen,Finn Egil Skjeldestad,Sven Eric Olsson,Margareta Steinwall,Darron R. Brown,Robert J. Kurman,Brigitte M. Ronnett,Mark H. Stoler,Alex Ferenczy,Diane M. Harper,Gretchen M. Tamms,Jimmy Yu,Lisa Lupinacci,Radha Railkar,Frank J. Taddeo,Kathrin U. Jansen,Mark T. Esser,Heather L. Sings,Alfred Saah,Eliav Barr +28 more
TL;DR: In this paper, a double-blind placebo-controlled phase II study was done to assess the efficacy of a prophylactic quadrivalent vaccine targeting the human papillomavirus (HPV) types associated with 70% of cervical cancers (types 16 and 18) and with 90% of genital warts (types 6 and 11).
Journal ArticleDOI
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials
TL;DR: Administration of HPV vaccine to HPV-naive women, and women who are already sexually active, could substantially reduce the incidence of HPV16/18-related cervical precancers and cervical cancer.
Journal ArticleDOI
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
Luisa L. Villa,Kevin A. Ault,Anna R. Giuliano,Ronaldo L.R. Costa,Carlos Alberto Petta,Rosires Pereira de Andrade,Darron R. Brown,Alex Ferenczy,Diane M. Harper,Laura A. Koutsky,Robert J. Kurman,Matti Lehtinen,Christian Malm,Sven Eric Olsson,Brigitte M. Ronnett,Finn Egil Skjeldestad,Margareta Steinwall,Mark H. Stoler,Cosette M. Wheeler,Frank J. Taddeo,Jimmy Yu,Lisa Lupinacci,Radha Railkar,Rocio D. Marchese,Mark T. Esser,Janine T. Bryan,Kathrin U. Jansen,Heather L. Sings,Gretchen M. Tamms,Alfred J. Saah,Eliav Barr +30 more
TL;DR: Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years), suggesting an anamnestic response.
Journal ArticleDOI
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.
Constance Mao,Laura A. Koutsky,Kevin A. Ault,Cosette M. Wheeler,Darron R. Brown,Dorothy J. Wiley,Frances B. Alvarez,Oliver Bautista,Kathrin U. Jansen,Eliav Barr +9 more
TL;DR: The vaccine HPV16 L1 VLP provides high-level protection against persistent HPV16 infection and HPV16-related CIN2–3 for at least 3.5 years after immunization, likely to reduce risk for cervical cancer.